A 52-year-old man with a 6-month history of pancytopenia undergoes bone marrow examination showing normocellular marrow with 8% blasts and dysplastic changes in all three cell lines. Cytochemical stains show MPO-positive blasts. Which investigation is most appropriate to confirm the diagnosis and assess prognosis?

Explanation

## Diagnostic Workup of Myelodysplastic Syndrome (MDS) ### Clinical Context The patient has pancytopenia with a normocellular marrow, dysplasia in all three lineages, and 8% blasts—findings consistent with MDS. Cytogenetic and molecular abnormalities are critical for diagnosis confirmation and risk stratification. ### Why Cytogenetic Analysis and Molecular Testing Are Essential **Key Point:** Cytogenetic abnormalities and molecular mutations are: - Required for MDS diagnosis (WHO criteria) - Essential for risk stratification (IPSS-R) - Predictive of progression to AML - Guide treatment decisions ### Cytogenetic Abnormalities in MDS: Prognostic Significance | Cytogenetic Finding | Prognosis | IPSS-R Risk | |---------------------|-----------|-------------| | Normal | Intermediate | Variable | | del(5q) | Favorable | Low | | del(20q), -Y | Favorable | Low | | +8, del(12p) | Intermediate | Intermediate | | -7, del(7q) | Adverse | High | | Complex (≥3 abnormalities) | Very adverse | Very high | | TP53 mutation | Adverse | High | | TP53 + complex karyotype | Very adverse | Very high | ### Diagnostic Algorithm for MDS ```mermaid flowchart TD A[Pancytopenia + dysplasia on marrow]:::outcome --> B{Blast percentage?}:::decision B -->|<5%| C[MDS-1]:::outcome B -->|5-9%| D[MDS-2]:::outcome B -->|10-19%| E[MDS-2 or AML-related]:::outcome C --> F[Cytogenetics + molecular testing]:::action D --> F E --> F F --> G{Abnormalities present?}:::decision G -->|Yes| H[MDS confirmed]:::outcome G -->|No| I[Repeat marrow or consider idiopathic dysplasia]:::action H --> J[IPSS-R risk stratification]:::action J --> K{Risk category?}:::decision K -->|Low| L[Supportive care ± lenalidomide]:::action K -->|High| M[Hypomethylating agents or transplant]:::action ``` **High-Yield:** MDS diagnosis requires: 1. Dysplasia in ≥10% of cells in one or more lineages 2. Blasts 5–19% (or <5% with cytogenetic abnormality) 3. Cytogenetic or molecular abnormality (or dysplasia alone if blasts ≥10%) ### Molecular Mutations in MDS **Mnemonic: ASXL-TP53-TET2-DNMT3A** (common mutations in MDS) - **ASXL1:** Adverse prognosis, associated with complex karyotype - **TP53:** Very adverse, predicts rapid progression - **TET2, DNMT3A:** Intermediate significance - **SRSF2, SF3B1:** Favorable in some contexts (SF3B1 with ring sideroblasts) **Clinical Pearl:** TP53 mutations + complex karyotype = highest risk for AML transformation and shortest overall survival. ### Why Other Options Are Insufficient - **LDH and uric acid:** Non-specific markers of cell turnover; do not confirm diagnosis or assess prognosis - **Flow cytometry alone:** Useful for detecting abnormal immunophenotype but does not replace cytogenetics for risk stratification - **Repeat biopsy in 3 months:** Delays diagnosis and does not provide the genetic information needed for treatment planning